Proposed Data Collections Submitted for Public Comment and Recommendations, 69972-69973 [05-22874]
Download as PDF
<![CDATA[
69972
Federal Register / Vol. 70, No. 222 / Friday, November 18, 2005 / Notices
mining industry. Mining has one of the
highest incidence rates for back pain of
any industry, and back injuries are
consistently the leading cause of lost
work days in the industry. The objective
of this project is to develop a selfadministered, paper and pencil risk
assessment tool for the development of
low back disorders specifically directed
towards use in the mining industry.
Many current methods of assessing the
risk of low back disorders do not
address stressors that are relatively
unique to the mining environment,
including the restricted vertical spaces
in many coal mines that require workers
to adopt stooping or kneeling postures
for extended periods of their workday.
The low back exposure assessment
tool for mining will assess various
occupational exposures associated with
development of back disorders in the
literature (postural demands, lifting,
whole body vibration exposure,
individual and psychosocial issues), as
well as specific mining stressors and
will develop a score that will be used
to assess the degree of risk for the job
and the individual. The tool will be
useful in both prioritizing jobs that need
interventions to reduce low back
disorder risk, and in evaluating the
effectiveness of interventions through
tool administration before and after the
implementation of an intervention.
There will be no cost to respondents
other than their time.
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
responses
per
respondent
Average
burden per
response
(in hours)
Respondents
Number of
respondents
Surface and Underground Miners .........................................................................
320 miners .....
1
15/60
80
Total ......................................................................................................................
........................
......................
......................
80
Dated: November 10, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 05–22873 Filed 11–17–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Data Collections Submitted
for Public Comment and
Recommendations
Proposed Project
Longitudinal Surveillance for
Beryllium Disease Prevention—
Extension—National Institute for
Occupational Safety and Health
(NIOSH)—Centers for Disease Control
and Prevention (CDC).
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–4766 and
send comments to Seleda Perryman,
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS–D74,
Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
Background and Brief Description
The mission of the National Institute
for Occupational Safety and Health
(NIOSH) is to promote safety and health
at work for all people through research
and prevention. The Occupational
Safety and Health Act, Pub. L. 91–596
(section 20[a][1]) authorizes the
National Institute for Occupational
Safety and Health (NIOSH) to conduct
research to advance the health and
safety of workers.
NIOSH has been conducting this
survey of beryllium workers for three
years and this extension will allow for
completion of the data collection.
Workers are asked to complete an
interviewer administered medical and
work history questionnaire and to give
a blood sample. Without medical and
work history data on former workers,
NIOSH staff will be unable to conduct
the necessary research to make
recommendations for preventing
beryllium sensitization and disease.
Centers for Disease Control and
Prevention
[60 Day–06–0463]
VerDate Aug<31>2005
15:21 Nov 17, 2005
Jkt 208001
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Total burden
hours
Follow-up on this cohort will provide
invaluable information on the natural
history of disease, gene-gene, and geneenvironment interactions, which can
become the basis for prevention policy
at both company and government levels.
Beryllium is a lightweight metal with
many applications. Exposed workers
may be found in the primary
production, nuclear power and
weapons, aerospace, scrap metal
reclamation, specialty ceramics, and
electronics industries, among others.
The size of the U.S. workforce at risk of
chronic beryllium disease (CBD), from
either current or past work-related
exposure to the metal, may be as high
as one million workers. Demand for
beryllium is growing worldwide, which
means that increasing numbers of
workers are likely to be exposed.
CBD is a chronic granulomatous lung
disease mediated through an
immunologic mechanism in workers
who become sensitized to the metal.
Sensitization can be detected with a
blood test called the beryllium
lymphocyte proliferation test (BeLPT),
which is used by the industry as a
surveillance tool. Use of this test for
surveillance was first reported in 1989.
Sensitized workers, identified through
workplace surveillance programs,
undergo clinical diagnostic tests to
determine whether they have CBD.
Research has indicated certain genetic
determinants in the risk of CBD; followup studies will be invaluable for further
characterizing the genetic contribution
to sensitization and disease.
NIOSH is in a unique position to
accomplish this research for a number
of reasons: (a) It has a successful
collaboration with the leading
E:\FR\FM\18NON1.SGM
18NON1
69973
Federal Register / Vol. 70, No. 222 / Friday, November 18, 2005 / Notices
jobs and tasks by physicochemical
characteristics, leading to an estimation
of dose rather than mass concentrationbased exposure. (c) It has pioneered the
evaluation of the dermal exposure route
in the beryllium sensitization process.
(d) It has developed and improved
genetic research that will contribute to
manufacturer of beryllium in the U.S.
This has allowed us to establish wellcharacterized worker cohorts within the
beryllium industry. (b) It is conducting
industrial hygiene research that should
significantly improve workplace-based
exposure assessment methods. This
research will allow characterization of
the understanding of risk variability in
sensitization and disease, as well as
discerning the underlying mechanisms.
(e) NIOSH has the institutional stability
to continue longitudinal evaluations of
health outcomes in relation to exposure
and genetic risk factors. There is no cost
to respondents other than their time.
ESTIMATES OF ANNUALIZED BURDEN HOURS
Respondents
Number of
respondents
Number of
responses /
respondent
Average
burden/response
(in hours)
Total burden
(in hours)
Former Workers ...............................................................................................
100
1
30/60
50
Dated: November 14, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 05–22874 Filed 11–17–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice and Solicitation for Written
Comments on the Draft CDC Health
Protection Research Guide, 2006–2015
Centers for Disease Control and
Prevention/Agency for Toxic Substances
and Disease Registry.
SUMMARY: The U.S. Centers for Disease
Control and Prevention/Agency for
Toxic Substances and Disease Registry
(hereto referred to as CDC) announces
the availability for public comment of
the draft CDC Health Protection
Research Guide, 2006–2015. CDC is
requesting input on this Research Guide
because maximizing the health impact
of public health research can only be
achieved through the collective efforts
of CDC, other Federal agencies, State
and local partners, academic partners,
business partners, non-profit
organizations, professional societies,
and the public. Please provide input on
any aspect of the Research Guide,
including but not limited to:
• Scope and use of the Research
Guide (including whether it has
identified the areas of health protection
research that most need to be addressed
within the next decade);
• Relevance and level of specificity of
the proposed research topics;
• Additions, deletions or
modifications to the proposed research
topics;
• Research Guide development
process; and
• Other improvements to the
Research Guide.
AGENCY:
VerDate Aug<31>2005
15:21 Nov 17, 2005
Jkt 208001
The public comment period is 60
days long. Written comments must be
received by close of business on January
15, 2006 at either of the addresses listed
below.
ADDRESSES: The draft CDC Health
Protection Research Guide, 2006–2015
is available for review by visiting the
Internet site, https://
www.rsvpBOOK.com/custom_pages/
50942/index.php, or by contacting
Jamila Rashid, PhD, Senior Health
Scientist, Centers for Disease Control
and Prevention, Office Of Public Health
Research, 1600 Clifton Road, NE., MD
D–72, Atlanta, GA 30333, 404–639–
4621, ResearchGuide@cdc.gov, for a
hard copy. Written comments may be
submitted electronically at the Internet
site or at the email address listed above.
Written comments may also be sent to
the mailing address above.
FOR FURTHER INFORMATION CONTACT:
Additional information about the CDC
Health Protection Research Guide is
available via the Office of Public Health
Research Web site, https://www.cdc.gov/
od/ophr/cdcra.htm or may be obtained
by communicating with the contact
whose name and telephone number is
listed above.
SUPPLEMENTATY INFORMATION: On
January 10, 2005, the Centers for Disease
Control and Prevention launched an
effort to develop its first ever, agencywide CDC Public Health Protection
Research Guide, 2006–2015. The new
Research Guide will address and
support CDC’s Health Protection Goals
(For additional information about the
Goals please see https://www.cdc.gov/
about/goals).
The Research Guide will also provide
overall guidance for CDC’s intramural
and extramural research as well as serve
as an effective planning and
communication tool for CDC’s public
health research.
The public comment period will give
researchers, representatives of CDC’s
DATES:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
key partner organizations and the public
the opportunity to voice their opinions
regarding the CDC Health Protection
Research Guide, 2006–2015 and the
future direction of CDC’s public health
research. The public comment period
will begin on November 18, 2005 and
end on January 15, 2006.
The Chief Science Officer, CDC, has
been delegated the authority to sign
general Federal Register notices for both
the CDC and ATSDR.
Dated: November 9, 2005.
Dixie E. Snider, Jr.,
Chief Science Officer, Centers for Disease
Control and Prevention.
[FR Doc. 05–22719 Filed 11–17–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare and Medicaid
Services
[Document Identifier: CMS–10174]
Emergency Clearance: Public
Information Collection Requirements
Submitted to the Office of Management
and Budget (OMB)
Center for Medicare and
Medicaid Services.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare and Medicaid
Services (CMS), Department of Health
and Human Services, is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
AGENCY:
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 70, Number 222 (Friday, November 18, 2005)]
[Notices]
[Pages 69972-69973]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-22874]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60 Day-06-0463]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-4766
and send comments to Seleda Perryman, CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail
to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Longitudinal Surveillance for Beryllium Disease Prevention--
Extension--National Institute for Occupational Safety and Health
(NIOSH)--Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The mission of the National Institute for Occupational Safety and
Health (NIOSH) is to promote safety and health at work for all people
through research and prevention. The Occupational Safety and Health
Act, Pub. L. 91-596 (section 20[a][1]) authorizes the National
Institute for Occupational Safety and Health (NIOSH) to conduct
research to advance the health and safety of workers.
NIOSH has been conducting this survey of beryllium workers for
three years and this extension will allow for completion of the data
collection. Workers are asked to complete an interviewer administered
medical and work history questionnaire and to give a blood sample.
Without medical and work history data on former workers, NIOSH staff
will be unable to conduct the necessary research to make
recommendations for preventing beryllium sensitization and disease.
Follow-up on this cohort will provide invaluable information on the
natural history of disease, gene-gene, and gene-environment
interactions, which can become the basis for prevention policy at both
company and government levels.
Beryllium is a lightweight metal with many applications. Exposed
workers may be found in the primary production, nuclear power and
weapons, aerospace, scrap metal reclamation, specialty ceramics, and
electronics industries, among others. The size of the U.S. workforce at
risk of chronic beryllium disease (CBD), from either current or past
work-related exposure to the metal, may be as high as one million
workers. Demand for beryllium is growing worldwide, which means that
increasing numbers of workers are likely to be exposed.
CBD is a chronic granulomatous lung disease mediated through an
immunologic mechanism in workers who become sensitized to the metal.
Sensitization can be detected with a blood test called the beryllium
lymphocyte proliferation test (BeLPT), which is used by the industry as
a surveillance tool. Use of this test for surveillance was first
reported in 1989. Sensitized workers, identified through workplace
surveillance programs, undergo clinical diagnostic tests to determine
whether they have CBD. Research has indicated certain genetic
determinants in the risk of CBD; follow-up studies will be invaluable
for further characterizing the genetic contribution to sensitization
and disease.
NIOSH is in a unique position to accomplish this research for a
number of reasons: (a) It has a successful collaboration with the
leading
[[Page 69973]]
manufacturer of beryllium in the U.S. This has allowed us to establish
well-characterized worker cohorts within the beryllium industry. (b) It
is conducting industrial hygiene research that should significantly
improve workplace-based exposure assessment methods. This research will
allow characterization of jobs and tasks by physicochemical
characteristics, leading to an estimation of dose rather than mass
concentration-based exposure. (c) It has pioneered the evaluation of
the dermal exposure route in the beryllium sensitization process. (d)
It has developed and improved genetic research that will contribute to
the understanding of risk variability in sensitization and disease, as
well as discerning the underlying mechanisms. (e) NIOSH has the
institutional stability to continue longitudinal evaluations of health
outcomes in relation to exposure and genetic risk factors. There is no
cost to respondents other than their time.
Estimates of Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden/
Respondents Number of responses / response (in Total burden
respondents respondent hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Former Workers.............................. 100 1 30/60 50
----------------------------------------------------------------------------------------------------------------
Dated: November 14, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. 05-22874 Filed 11-17-05; 8:45 am]
BILLING CODE 4163-18-P
